Author Interviews, OBGYNE / 06.04.2019
Medication Abortion Rebounded in Texas After FDA Approved Label Change for Mifeprex®
MedicalResearch.com Interview with:
Sarah Baum, MPH
investigator at the Texas Policy Evaluation Project
Associate at Ibis Reproductive Health
MedicalResearch.com: What is the background for this study?
Response: Before 2013, use of medication abortion in Texas mirrored national trends, which have steadily increased since the approval of mifepristone--one of the two medications used for medication abortion--in 2000. However, House Bill 2 (HB 2), which was implemented on November 1, 2013, imposed restrictions on medication abortion and required providers to follow the outdated mifepristone label. HB 2 reduced the gestational age limit to 49 days and generally required four visits.
On March 29, 2016, the US Food and Drug Administration (FDA) approved a revised label for Mifeprex® (mifepristone 200 mg) that reflected evidence-based practice, which essentially nullified the medication abortion restrictions in HB 2. The label change brought medication abortion prescribing guidelines in line with evidence-based practice, reducing the number of required in-person visits from four to two and extending the period when patients can take the pill from seven weeks of pregnancy to 10 weeks. (more…)